Tenax Therapeutics (NASDAQ:TENX) Stock: Insider Adar1 Capital Management, Llc Buys 331,979 Shares

Posted by Lauren Steadman on Oct 21st, 2026

Tenax Therapeutics, Inc. (NASDAQ:TENX – Get Free Report) major shareholder Adar1 Capital Management, Llc acquired 331,979 shares of the stock in a transaction dated Wednesday, October 21st. The shares were bought at an average price of $1.66 per share, with a total value of $551,085.14. Following the completion of the purchase, the insider directly owned 7,447,000 shares of the company’s stock, valued at approximately $12,362,020. This trade represents a 4.67% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

On Tuesday, October 20th, Adar1 Capital Management, Llc bought 254,342 shares of Tenax Therapeutics stock. The stock was purchased at an average cost of $1.60 per share, for a total transaction of $406,947.20.
On Monday, October 19th, Adar1 Capital Management, Llc bought 336,528 shares of Tenax Therapeutics stock. The stock was purchased at an average cost of $1.51 per share, for a total transaction of $508,157.28.
On Thursday, September 3rd, Adar1 Capital Management, Llc bought 900,000 shares of Tenax Therapeutics stock. The stock was purchased at an average price of $1.78 per share, with a total value of $1,602,000.00.
On Wednesday, September 2nd, Adar1 Capital Management, Llc purchased 187,704 shares of Tenax Therapeutics stock. The shares were purchased at an average cost of $1.80 per share, with a total value of $337,867.20.
On Tuesday, September 1st, Adar1 Capital Management, Llc purchased 179,058 shares of Tenax Therapeutics stock. The shares were purchased at an average cost of $1.80 per share, with a total value of $322,304.40.
On Monday, August 31st, Adar1 Capital Management, Llc acquired 403,571 shares of Tenax Therapeutics stock. The stock was purchased at an average price of $1.79 per share, with a total value of $722,392.09.
On Monday, August 24th, Adar1 Capital Management, Llc acquired 107,374 shares of Tenax Therapeutics stock. The stock was purchased at an average price of $1.75 per share, with a total value of $187,904.50.
On Friday, August 21st, Adar1 Capital Management, Llc bought 716,369 shares of Tenax Therapeutics stock. The shares were purchased at an average cost of $1.77 per share, with a total value of $1,267,973.13.
On Thursday, August 20th, Adar1 Capital Management, Llc bought 202,124 shares of Tenax Therapeutics stock. The shares were purchased at an average cost of $1.78 per share, with a total value of $359,780.72.

Tenax Therapeutics Stock Performance

NASDAQ TENX remained flat at $1.63 during trading hours on Wednesday. The company had a trading volume of 1,889,406 shares, compared to its average volume of 2,241,564. The company’s 50-day moving average is $1.85 and its two-hundred day moving average is $9.25. The stock has a market cap of $60.99 million, a PE ratio of -1.10 and a beta of 0.92. Tenax Therapeutics, Inc. has a 52-week low of $1.31 and a 52-week high of $19.40.

Tenax Therapeutics (NASDAQ:TENX – Get Free Report) last issued its quarterly earnings results on Friday, July 31st. The specialty pharmaceutical company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.03. On average, equities analysts forecast that Tenax Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on TENX. Guggenheim downgraded shares of Tenax Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday, August 31st. Wall Street Zen cut shares of Tenax Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. UBS Group downgraded shares of Tenax Therapeutics to a “neutral” rating in a research report on Monday, August 31st. William Blair lowered shares of Tenax Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, August 10th. Finally, Weiss Ratings lowered shares of Tenax Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, September 14th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $14.00.

Get Our Latest Research Report on TENX

Institutional Investors Weigh In On Tenax Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC increased its holdings in Tenax Therapeutics by 989.3% in the 1st quarter. Janus Henderson Group PLC now owns 1,815,474 shares of the specialty pharmaceutical company’s stock worth $29,066,000 after acquiring an additional 1,648,808 shares in the last quarter. Perceptive Advisors LLC grew its position in shares of Tenax Therapeutics by 229.7% in the first quarter. Perceptive Advisors LLC now owns 1,447,782 shares of the specialty pharmaceutical company’s stock valued at $23,150,000 after purchasing an additional 1,008,640 shares during the period. Braidwell LP acquired a new stake in shares of Tenax Therapeutics in the second quarter valued at about $8,503,000. Bank of New York Mellon Corp purchased a new stake in shares of Tenax Therapeutics during the second quarter worth about $4,733,000. Finally, Avidity Partners Management LP purchased a new stake in shares of Tenax Therapeutics during the first quarter worth about $3,453,000. Institutional investors and hedge funds own 1.67% of the company’s stock.

About Tenax Therapeutics

(Get Free Report)

Tenax Therapeutics, Inc is a specialty pharmaceutical company focused on developing treatments for cardiovascular and pulmonary diseases with significant unmet medical needs. The company’s research and development activities are centered on therapies intended to improve outcomes for patients with conditions affecting the heart and lungs.

Tenax’s primary product candidate is an oral formulation of levosimendan, a drug designed to enhance cardiac contractility and produce vasodilatory effects.